Author:
Wild Claudia,Götz Gregor,Wernly Bernhard
Subject
Cardiology and Cardiovascular Medicine
Reference15 articles.
1. G. Goetz, B. Wernly, Wearable cardioverter-defibrillator (WCD) therapy for primary and secondary prevention of sudden cardiac arrest, Update 2022, Decision Support Document 103/ 2. Update 2022: 2022 [cited 24.10.2022], Available from: https://eprints.aihta.at/1407/.
2. M. Nürnberg, F. Semrau, Critical appraisal of “Goetz G, Wernly B, Wild C (2023) Wearable cardioverter defibrillator for preventing sudden cardiac death in patients at risk: An updated systematic review of comparative effectiveness and safety. IJC Heart & Vasculature 45 (2023) 101189”, Int. J. Cardiol. Heart Vasc. 48 (2023) 101258, Epub 20230830, doi: 10.1016/j.ijcha.2023.101258.
3. J.E. Olgin, M.J. Pletcher, E. Vittinghoff, J. Wranicz, R. Malik, D.P. Morin, et al., Wearable cardioverter-defibrillator after myocardial infarction, N. Engl. J. Med. 379(13) (2018) 1205–1215, doi: 10.1056/NEJMoa1800781, Epub 2018/10/04.
4. M. Weiss, G. Michels, F. Eberhardt, W. Fehske, S. Winter, F. Baer, et al., Anxiety, depression and quality of life in acute high risk cardiac disease patients eligible for wearable cardioverter defibrillator: Results from the prospective multicenter CRED-registry, PLoS One 14(3) (2019) e0213261, doi: 10.1371/journal.pone.0213261, Epub 2019/03/12.
5. Institute of Health Economics (IHE), Quality Appraisal Checklist for Case Series, 2016 [cited 01.07.2022], Available from: https://www.ihe.ca/research-programs/rmd/cssqac/cssqac-about.